This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

AstraZeneca (AZN) Receives a Buy from Bernstein

Tipranks - Tipranks - Tue Jul 7, 5:58AM CDT

In a report released today, Justin Smith from Bernstein maintained a Buy rating on AstraZeneca, with a price target of £189.00.

4th of July Sale - 70% Off

According to TipRanks, Smith is a 4-star analyst with an average return of 11.6% and a 68.70% success rate. Smith covers the Healthcare sector, focusing on stocks such as AstraZeneca, GlaxoSmithKline, and Roche Holding AG.

In addition to Bernstein, AstraZeneca also received a Buy from Bank of America Securities’s Sachin Jain in a report issued today. However, on June 30, Deutsche Bank maintained a Sell rating on AstraZeneca (LSE: AZN).

See the top stocks recommended by analysts >>

Based on AstraZeneca’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of p15.29 billion and a net profit of p3.08 billion. In comparison, last year the company earned a revenue of p13.96 billion and had a net profit of p3 billion

Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AZN in relation to earlier this year.

Read More on GB:AZN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).